1. Home
  2. PHVS vs WEAV Comparison

PHVS vs WEAV Comparison

Compare PHVS & WEAV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PHVS
  • WEAV
  • Stock Information
  • Founded
  • PHVS 2015
  • WEAV 2011
  • Country
  • PHVS Switzerland
  • WEAV United States
  • Employees
  • PHVS N/A
  • WEAV N/A
  • Industry
  • PHVS Biotechnology: Pharmaceutical Preparations
  • WEAV EDP Services
  • Sector
  • PHVS Health Care
  • WEAV Technology
  • Exchange
  • PHVS Nasdaq
  • WEAV Nasdaq
  • Market Cap
  • PHVS 980.3M
  • WEAV 613.5M
  • IPO Year
  • PHVS 2021
  • WEAV 2021
  • Fundamental
  • Price
  • PHVS $18.60
  • WEAV $8.79
  • Analyst Decision
  • PHVS Buy
  • WEAV Strong Buy
  • Analyst Count
  • PHVS 6
  • WEAV 5
  • Target Price
  • PHVS $37.17
  • WEAV $16.10
  • AVG Volume (30 Days)
  • PHVS 35.9K
  • WEAV 982.1K
  • Earning Date
  • PHVS 08-13-2025
  • WEAV 07-30-2025
  • Dividend Yield
  • PHVS N/A
  • WEAV N/A
  • EPS Growth
  • PHVS N/A
  • WEAV N/A
  • EPS
  • PHVS N/A
  • WEAV N/A
  • Revenue
  • PHVS N/A
  • WEAV $212,950,000.00
  • Revenue This Year
  • PHVS N/A
  • WEAV $18.69
  • Revenue Next Year
  • PHVS N/A
  • WEAV $15.71
  • P/E Ratio
  • PHVS N/A
  • WEAV N/A
  • Revenue Growth
  • PHVS N/A
  • WEAV 19.58
  • 52 Week Low
  • PHVS $11.51
  • WEAV $7.91
  • 52 Week High
  • PHVS $25.50
  • WEAV $17.63
  • Technical
  • Relative Strength Index (RSI)
  • PHVS 60.00
  • WEAV 48.59
  • Support Level
  • PHVS $16.72
  • WEAV $7.98
  • Resistance Level
  • PHVS $17.53
  • WEAV $8.68
  • Average True Range (ATR)
  • PHVS 0.93
  • WEAV 0.36
  • MACD
  • PHVS 0.07
  • WEAV 0.05
  • Stochastic Oscillator
  • PHVS 92.86
  • WEAV 85.44

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

About WEAV Weave Communications Inc.

Weave Communications Inc is a customer experience and payments software platform tailored for SMB healthcare businesses, that revolutionizes patient interaction from initial contact to billing. It integrates diverse workflows into a unified solution, minimizing manual tasks and maximizing patient engagement. Weave democratizes enterprise-level communication tools, simplifying them for SMBs in a singular platform. Offering varied communication channels, appointment scheduling, payment processing, and more, enhances practitioner-patient relationships and optimizes practice operations. The company has a singular operating segment and revenue primarily from subscription services.

Share on Social Networks: